Asthma is associated with higher rates of acute chest syndrome (ACS) and vaso-occlusive pain episodes among children with sickle cell anaemia (SCA). Aeroallergen sensitization is a risk factor for asthma. We hypothesized that aeroallergen sensitization is associated with an increased incidence of hospitalizations for ACS and pain. Participants in a multicentre, longitudinal cohort study, aged 4-18 years with SCA, underwent skin prick testing to ten aeroallergens. ACS and pain episodes were collected from birth until the end of the follow-up period. The number of positive skin tests were tested for associations with prospective rates of ACS and pain. Multivariable models demonstrated additive effects of having positive skin tests on future rates of ACS (incidence rate ratio (IRR) for each positive test 1Á23, 95% confidence interval [CI] 1Á11-1Á36, P < 0Á001). Aeroallergen sensitization was not associated with future pain (IRR 1Á14, 95%CI 0Á97-1Á33, P = 0Á11). Our study demonstrated that children with SCA and aeroallergen sensitization are at increased risk for future ACS. Future research is needed to determine whether identification of specific sensitizations and allergen avoidance and treatment reduce the risk of ACS for children with SCA.
Summary
Asthma is associated with higher rates of acute chest syndrome (ACS) and vaso-occlusive pain episodes among children with sickle cell anaemia (SCA). Aeroallergen sensitization is a risk factor for asthma. We hypothesized that aeroallergen sensitization is associated with an increased incidence of hospitalizations for ACS and pain. Participants in a multicentre, longitudinal cohort study, aged 4-18 years with SCA, underwent skin prick testing to ten aeroallergens. ACS and pain episodes were collected from birth until the end of the follow-up period. The number of positive skin tests were tested for associations with prospective rates of ACS and pain. Multivariable models demonstrated additive effects of having positive skin tests on future rates of ACS (incidence rate ratio (IRR) for each positive test 1Á23, 95% confidence interval [CI] 1Á11-1Á36, P < 0Á001). Aeroallergen sensitization was not associated with future pain (IRR 1Á14, 95%CI 0Á97-1Á33, P = 0Á11). Our study demonstrated that children with SCA and aeroallergen sensitization are at increased risk for future ACS. Future research is needed to determine whether identification of specific sensitizations and allergen avoidance and treatment reduce the risk of ACS for children with SCA.
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Sickle cell anaemia (SCA) is the most common inherited blood disease in the United States. The most common complications for patients with SCA include acute vaso-occlusive pain (herein referred to as "pain") and acute chest syndrome (ACS) Platt et al, 1994) . Previous studies have demonstrated that children with SCA and asthma have increased rates of ACS and pain and increased risk for premature death compared to those without asthma (Boyd et al, 2007; Bernaudin et al, 2008) . Atopy is the most significant risk factor for the development of childhood asthma in the general population, with an increased risk of 10-to 20-fold (Burrows et al, 1989) . Previous studies in children with SCA have demonstrated associations between markers of atopy [positive allergy skin tests (Knight-Madden et al, 2005; Strunk et al, 2014) and elevated total IgE ] and a history of prior ACS.
Given this previous evidence suggesting that indicators of atopy may be associated with greater morbidity among children with SCA, we sought to further characterize this relationship. We hypothesized that aeroallergen sensitization is associated with an increased incidence of ACS episodes in children with SCA. The objectives of the current study were: (i) to determine the prevalence of aeroallergen sensitization among an unselected cohort of children with SCA using skin prick testing; (ii) to examine associations between aeroallergen sensitization and prospective rates of pain and ACS; and (iii) to explore whether scores on a composite index of atopy features (herein termed the "Atopy Index") would be associated with prospective morbidity in children with SCA.
Methods

Study design
Data were collected as part of the prospective, observational Sleep and Asthma Cohort (SAC) study. Between 2005 and 2011, children aged 4-18 years with SCA (haemoglobin SS or Sb 0 ) were enrolled at three clinical centres (St. Louis, MO, Cleveland, OH and London, UK) without regard to previous morbidity or diagnosis of asthma. Serum IgE and complete blood count were obtained at study entry. Percentage of blood eosinophils was determined using standard techniques at each clinical centre. Medical records of participants were reviewed to obtain the number of hospitalizations for pain and ACS episodes, both retrospectively (from birth whenever possible) and prospectively, until the end of the study period in 2013 or until participants were lost to follow-up. Medical records of participants were also reviewed in order to determine asthma history. Asthma was defined in our cohort as a physician diagnosis of asthma in the medical record plus a prescription for an asthma medication, such as short-acting beta agonist (SABA) and/or inhaled corticosteroid (ICS) . Children were ineligible for the study if they were receiving chronic transfusion therapy or participating in a clinical trial evaluating hydroxycarbamide therapy at the time of recruitment. However, participants were able to continue their participation if they were subsequently prescribed chronic transfusions or hydroxycarbamide therapy during the follow-up period. Participating sites had institutional approval. Written informed consent was obtained from parents and assent was obtained from children at enrolment according to institutional policies.
Allergy skin testing
Participants underwent allergy skin prick testing at study entry, performed by SAC-certified technicians using the Multi-test II (Lincoln Diagnostics, Decatur, IL). Ten aeroallergens (Greer Laboratories, Lenoir, NC) were used for skin testing including: Aspergillus fumigatus, house dust mite (Dermatophagoides pteronyssinus and Dermatophagoides farinae), cockroach (American and German), cat (standardized), dog (mixed breeds), mouse, Alternaria alternata, grass (standardized southern mix), tree (eastern 8 tree mix) and weed (national mix). Skin tests were administered with histamine (positive) and saline (negative) controls. Tests were considered positive when the mean diameter of the wheal was ≥3 mm. Wheal reactions were traced onto translucent acetate paper and measured centrally by a single investigator for quality control of the results.
Definition of vaso-occlusive pain episode and acute chest syndrome ACS was defined as a new radiographic pulmonary infiltrate in the context of an acute respiratory illness with symptoms such as cough, wheezing, rales, chest pain, decreased oxygen saturation >2% from baseline, use of accessory muscles of respiration or increased respiratory rate, with or without fever. Pneumonia was considered an ACS episode. A pain episode was defined as a hospitalization for SCA-associated pain, excluding headaches, and requiring opioid treatment.
Headaches were excluded from this definition because of the presumed difference in pathophysiology (Dowling et al, 2014) . All ACS and pain episodes were reviewed by a single investigator at each participating site with over-reading by the principal investigator, to ensure uniform definitions of ACS and pain episodes in this multi-centre study.
Atopy index
The Atopy Index is a novel evaluation tool created for the purpose of this investigation and was based on 4 factors and their known associations with atopy in children as well as a potential association with SCA-related morbidity and included: aeroallergen sensitization (Lipozen ci c & Wolf, 2010; Strunk et al, 2014) , serum IgE level , peripheral blood eosinophils (Canalli et al, 2004 ) and a history of asthma in either parent . Z-scores for IgE levels were calculated for our cohort using normative data from race-, age-, and gender-matched controls from National Health and Nutrition Examination Survey 
Statistical analysis
The number of positive skin tests (out of a possible 10) was used as a continuous variable; however, because of low numbers, individuals with 6 or more positive tests were grouped together. Associations between the number of positive skin tests and prospective rates of ACS and pain after the date of skin testing were tested with negative binomial regression models. Analyses were limited to participants with ACS and pain data from birth and a minimum of 12 months of prospective follow-up after skin testing. Multivariable models were built in two steps. Potential covariates were included in a screening model. In addition to the number of positive skin tests, covariates that were considered to be potentially associated with prospective rates of ACS included sex, ACS prior to 4 years of age , white blood cell count, IgE level , fractional exhaled nitric oxide (FeNO), asthma diagnosis (Boyd et al, 2006) , parental asthma and history of wheezing leading to shortness of breath . Covariates considered for inclusion in the model for prospective rates of pain were gender, age, white blood cell count, history of wheeze leading to shortness of breath (Glassberg et al, 2006) , and haemoglobin level. Following analyses with the number of positive skin tests, we constructed additional models to test associations between the score on the Atopy Index and prospective rates of ACS and pain. All covariates with P < 0Á20 in screening models were included in the final ACS and pain models. Models for the Atopy Index were compared to models for positive skin tests alone using the Likelihood test. Analyses were conducted using STATA statistical software (Version 12, StataCorp LP, College Station, TX) and IBM SPSS Statistics (Version 22, IBM, Chicago, IL).
Results
Recruitment and demographics
Of the 252 SAC participants, 188 had morbidity data available from birth and 165 had acceptable allergy skin test data, with a mean of 5Á0 years (standard deviation [SD] AE1Á2 years) of prospective follow-up after skin testing. Ninety-eight participants (59%) did not have aeroallergen sensitization, while 67 participants (41%) had at least one positive skin test (Fig 1) . Clinical characteristics of the cohort are summarized in Table I . Children with at least one positive skin test had higher IgE levels than those who did not (P = 0Á01). Individuals were also more likely to have a positive skin test if they had a parent with asthma (P = 0Á01). The participants excluded from the analysis due to missing or invalid allergy skin test data were older (mean age 13Á8 years compared to 10Á0 years, P < 0Á01) and had a slightly higher IgE level (median 51 500 g/l compared to 27 000 g/l, P = 0Á05) compared to those who were included. These comparisons are summarized in Table SI . A total of 163 participants had complete data on all covariates used in our models and were therefore included in the analysis.
Positive skin test is predictive of future ACS rate but not future pain Multivariable models demonstrated additive significant effects of having positive skin tests on future rates of ACS such that each increase of 1 positive test was associated with a 23% increased rate of future ACS episodes (95% confidence interval [CI] 11-36%, P < 0Á001) (Table II) . In a multivariable model, aeroallergen sensitization was not a significant predictor of pain incidence rates (incidence rate ratio [IRR] 1Á14, 95% CI 0Á97-1Á33, P = 0Á11).
Allergy skin testing provides additional information beyond asthma diagnosis
Aeroallergen sensitization does not appear to be simply a proxy for asthma status in our cohort. Although more children with asthma had at least one positive skin test compared to children without asthma (50% vs. 36%), this difference was not statistically significant (P = 0Á09). Additionally, in analyses stratified by asthma status, the number of positive skin tests was significantly associated with increased rates of ACS among children without asthma, but not among children with a diagnosis of asthma (Table III) .
Atopy index is not more predictive of future ACS than allergy skin testing alone Within our cohort, 132 participants had complete data for all four variables included in the Atopy Index. The Atopy Index was a significant predictor of future rates of ACS (IRR 1Á44, 95% CI 1Á17-1Á76, P < 0Á001) (Table IV) , but was not associated with future rates of pain (IRR 1Á14, 95% CI 0Á82-1Á58, P = 0Á43). Using the likelihood test to compare models, the Atopy Index did not perform better than having at least one positive skin test in predicting future episodes of ACS (likelihood test P value = 0Á22), demonstrating that having a positive skin test was the critical covariate in the index. 
Discussion
Asthma in SCA is a known risk factor for increased acute vaso-occlusive pain, ACS and earlier death. However, the diagnosis of asthma is difficult in children with SCA, particularly because many features of asthma occur in individuals with SCA that do not have asthma, such as cough, wheezing, and airway hyper-reactivity. Our study demonstrates for the first time that even a single positive skin test confers a significantly increased risk for future ACS and, more importantly, that increasing numbers of positive skin tests are associated with increased rates of prospective ACS. Furthermore, aeroallergen sensitization also seems to be the most significant indicator of atopy associated with SCA-related morbidity. The addition of other manifestations of atopy, including elevated ACS, acute chest syndrome; SCA, sickle cell anaemia; IRR, incidence rate ratio; CI, confidence interval. *Negative binomial regression models with adjustment for over-dispersion, using robust standard errors. Two-tailed significance values. ACS, acute chest syndrome; SCA, sickle cell anaemia; IRR, incidence rate ratio; CI, confidence interval. *Negative binomial regression models with adjustment for over-dispersion, using robust standard errors. Two-tailed significance values.
IgE levels, eosinophilia and parental asthma, to having a positive skin test did not improve our ability to predict ACS. While there is strong evidence that a physician diagnosis of asthma is a risk factor for ACS (Knight-Madden et al, 2005; Boyd et al, 2007; Sylvester et al, 2007; Cohen et al, 2011) , aeroallergen sensitization does not seem to be merely a marker of asthma status among children with SCA. In our cohort, we demonstrated a significant impact of aeroallergen sensitization on future ACS episodes in children without a doctor diagnosis of asthma. One potential explanation for this finding is that for children with SCD and asthma, the airways are already primed for exaggerated inflammatory response to a multitude of triggers -allergic, infectious or other. In those children, a history of early life ACS is the best predictor of future ACS. In contrast, for non-asthmatic individuals whose airways aren't as hyper-responsive to other triggers, exposure to an allergic trigger in the setting of aeroallergen sensitization is a significant factor associated with acute respiratory episodes, including ACS (DeBaun & Strunk, 2016) . Furthermore, our data demonstrates a nearly 2-fold increase in the risk of future ACS episodes with a history of ACS prior to age 4 years in those participants with asthma compared to those without an asthma diagnosis (Table III) . In children with SCA without asthma, there may be more unexplained variation that allows detection by other covariates, such as the number of positive aeroallergen skin tests. Our results differ from a prior study of 340 children with SCA in the Silent Cerebral Infarct Transfusion (SIT) trial which found that having a positive serum allergen-specific IgE test to Alternaria, cockroach (B. germanica) or dust mite (D. pteronyssinus) was not associated with increased risk of ACS or pain episodes . However, the SIT Trial only included a limited panel of antibody testing to 3 aeroallergens. Serum aeroallergen-specific IgE testing to expanded panels of indoor (i.e., cat, dog, mouse, dust mite, cockroach, indoor moulds) and outdoor (i.e., tree and grass pollens, ragweeds, outdoor moulds) allergens are widely available, results are not invalidated when a patient is taking antihistamines, and only require a simple blood draw. Further research is needed to determine whether an expanded panel of aeroallergen-specific IgE testing, which is probably more feasible for providers caring for children with SCA, represents a satisfactory alternative to skin testing in this population.
Studies from transgenic sickle cell disease (SCD) mouse models offer a proposed mechanism for the connection between atopy and increased incidence of ACS episodes. Ovalbumin sensitized sickle mice have increased interleukin 5 levels and increased airway resistance compared to HbA mice (Pritchard et al, 2012) , and when exposed to additional aerosolized ovalbumin, sickle mice have increased histological evidence of airway and vascular inflammation, and increased risk of death compared to control mice (Nandedkar et al, 2008) . Andemariam et al has also demonstrated increased ovalbumin-induced allergic airway inflammation in sickle mice compared to wild type mice, including increased bronchoalveolar lavage, leucocytosis and eosinophilia, increased ovalbumin-specific serum IgE levels and altered inflammatory cytokine profiles in SCD mice compared to control mice (Andemariam et al, 2015) . These findings suggest that the pro-inflammatory state of SCD may prime the immune system to be hyper-responsive to inhaled allergens, and thus may help explain the high morbidity seen in patients with asthma and SCD. Eiymo Mwa Mpollo et al (2016) examined whether placental growth factor (PGF), a member of the vascular endothelial growth factor family known to be increased among patients with SCD, may be a potential mediator on the pathway between allergic sensitization and SCD morbidity. In a series of experiments, they demonstrated that PGF knockout (Pgf À ) mice have significantly less airway resistance, airway hyperresponsiveness, circulating IgE, airway eosinophilia, and goblet cell hyperplasia compared to wild type Pgf + mice. Furthermore, these investigators found that intratracheal exposure to house dust mite allergen extract was associated with upgregulation of plasma PGF levels in wild type mice. When the investigators then examined sickle mice, they noted exaggerated responses to house dust mite airway exposure in terms of airway hyper-responsiveness, and this finding was mediated by PGF through a leukotriene-dependent pathway. When sickle mice were treated with PGF antibodies and zileuton (a leukotriene synthesis inhibitor), house dust mite-exposure-induced airway reactivity was significantly decreased (Eiymo Mwa Mpollo et al, 2016) . Taken together, these data strongly suggest that individuals with SCD and asthma have airways that may be primed for an exaggerated response to a trigger, such as a viral respiratory infection in young children. This offers a mechanism for the high predictability of an ACS episode prior to age 4 years predicting future episodes of ACS. Additionally, the airways of children with SCD may have a predisposition to airway inflammation that is primed for aeroallergen sensitization leading to future ACS events. Furthermore, a single centre study demonstrated a benefit of daily inhaled corticosteroids in non-asthmatic adult patients with SCD (Glassberg et al, 2017) . Strengths of the current study include the rigorous data collection methods. All SCA-related morbidity data and The results of the current study provide additional evidence that determination of aeroallergen sensitization, as detected by skin testing, is an objective strategy for identifying a subgroup of children at increased risk of developing ACS episodes. These results, coupled with other studies from the same cohort, demonstrate that aeroallergen sensitization, wheezing causing shortness of breath and an ACS event prior to age 4 years, are easily identifiable risk factors for future ACS events in children with SCA . Additional studies are needed to determine if identifying children with SCA and allergic sensitization, along with strategies aimed at minimizing exposures to and maximizing treatment of the manifestations of aeroallergen sensitization, can decrease rates of future ACS episodes.
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